Completed PHASE2 INTERVENTIONAL NCT00003878

Carmustine Implants in Treating Patients With Brain Metastases

The Treatment of One or Two Supratentorial Brain Metastases With Surgical Resection and BCNU-Polymer Wafers

Sponsor: National Cancer Institute (NCI)

Conditions Metastatic Cancer Unspecified Adult Solid Tumor, Protocol Specific

Interventions conventional surgery polifeprosan 20 with carmustine implant

Updated 5 times since 2017 Last updated: Jun 20, 2013 Started: Apr 30, 2002 Completion: Apr 30, 2003

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00003878, this PHASE2 trial focuses on Metastatic Cancer and Unspecified Adult Solid Tumor, Protocol Specific and remains completed. Sponsored by National Cancer Institute (NCI), it has been updated 5 times since 2002, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Apr 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)
New Approaches to Brain Tumor Therapy Consortium

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Baltimore, United States , Birmingham, United States , Boston, United States , Chapel Hill, United States , Cleveland, United States , Detroit, United States , Philadelphia, United States , San Antonio, United States , Tampa, United States and 1 more location